Foreign pharmaceutical companies are ready to provide Ukraine with instruments that will give access to innovative medicines without reducing the level of protection of intellectual property rights. “The companies that are members of the American Chamber of Commerce in Ukraine are ready to actively join this work and cooperate with all the interested parties to ensure effective solutions,” Vitaliy Gordienko, the co-chairman of the American Chamber of Commerce’s (AmCham) Healthcare Committee, said when presenting the issues of patients’ access to innovative medicines, which took place in Kyiv at the beginning of the week.
He stressed that non-compliance with patent law and a lack of intellectual property rights protection does not entail a reduction in prices for medicines.
At the same time, innovative pharmaceutical companies that are members of AmCham are ready to provide Ukraine with appropriate mechanisms to reduce prices and ensure equal access to medicines, in particular, confidential negotiation procedures, free goods, long-term contracts, direct contracts.
At the same time, Ukraine should create a regulatory framework for the application of a negotiation procedure, in particular, in the sphere of budget purchases.
Gordienko also drew attention to the importance of introducing the national list of essential medicines. However, according to the expert, the procedure of including drugs in the national list should not exclude the possibility of getting into it of innovative drugs that are used, in particular, at the secondary and tertiary levels of medical care.
